Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 maraviroc pharmacokinetics, safety, and efficacy study in treatment-experienced children and adolescents with CCR5-tropic HIV-1
2008-006873-33Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maraviroc in Human immunodeficiency virus infection type 1, sponsored by Pfizer. Primary endpoint: Average maraviroc concentration. Started Jan 2009; status: completed.
02
Drugs
maraviroc
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2008-006873-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006873-33.